What was studied? We wanted to see whether having pharmacists closely involved in cancer care improves medication safety and reduces severe side effects for patients with gynecologic cancers (like ovarian or uterine cancer) during chemotherapy. How was the study done? Who participated? Patients receiving chemotherapy at Peking University First Hospital's Gynecologic Oncology Ward (September 2022-September 2024). Two groups compared: Standard care group: Pharmacists provided routine pharmaceutical services. Full pharmacy care group: Pharmacists provided ongoing support, including: Checking medications for safety. Teaching patients how to manage side effects. Answering questions about drugs. Helping manage reactions like nausea or low white blood cells. What was measured? Severe side effects (e.g., extreme nausea, appetite loss), how well doctors prescribed and monitored medications to boost white blood cells, and unplanned hospital stays. Key findings: Patients with full pharmacy care had: Fewer severe side effects: Less extreme nausea, appetite loss, and dangerously low white blood cell counts. Better management of blood cell-boosting medications: Doctors followed guidelines more closely, and patients received proper monitoring. Fewer unplanned hospital visits: Likely due to better side effect prevention and early intervention. Why does this matter? For patients: Pharmacist support during chemotherapy may help you avoid severe side effects and reduce unexpected hospital stays. For families: Knowing pharmacists are actively involved can provide reassurance about your loved one's medication safety. For healthcare teams: Structured pharmacist collaboration improves adherence to treatment guidelines and patient outcomes. Takeaway: Full pharmacy care throughout chemotherapy helps protect patients' safety, reduces severe reactions, and supports smoother treatment journeys.
Age range
18 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Degree of myelosuppression
Timeframe: From enrollment to the end of treatment at 3 weeks